Literature DB >> 22161476

Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes.

Zongling Xia1, Mingli Wang, Sulan Zou, Rong Chen.   

Abstract

The present study investigated inhibitory effects of 1,4-dihydropyridines (1,4-DHPs) calcium channel antagonists (1,4-DHP-CCAs) on cytochromeP450 3A4 (CYP3A4) of human liver microsomes and further explored importance of 1,4-DHPs molecular structural descriptors. Partial Least Squares method was applied to probe the quantitative relationships between the 1,4-DHPs molecular structural descriptors and its inhibitory actions, which demonstrated that different 1,4-DHP-CCAs could inhibit CYP3A4 enzyme's activity differently. The K (i) values of nicardipine, lercandipine, cilnidipine, nitrendipine, lacidipine, nifedipine, felodipine were 10.13, 10.17, 11.44, 23.90, 29.34, 29.06 and 32.64 μmol L⁻¹, respectively. It is suggested that the 1,4-DHPs molecular structural descriptors are the most important for its inhibitory effects based on the quantitative structure-activity relationship (QSAR) formula. The LogP was positively correlated to the K (i), whereas molecular weight and molecule volume were negatively correlated. It is concluded that analysis of K (i) of 1,4-DHPs derivatives on the CYP3A4 activity may apply for the QSAR formula at the initial stage of clinical application of new drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22161476     DOI: 10.1007/s13318-011-0076-3

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  25 in total

Review 1.  Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles.

Authors:  D F Lewis
Journal:  Toxicology       Date:  2000-04-03       Impact factor: 4.221

Review 2.  Calcium channel blockers in treatment of hypertension.

Authors:  J Muntwyler; F Follath
Journal:  Prog Cardiovasc Dis       Date:  2001 Nov-Dec       Impact factor: 8.194

3.  Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates.

Authors:  D M Stresser; A P Blanchard; S D Turner; J C Erve; A A Dandeneau; V P Miller; C L Crespi
Journal:  Drug Metab Dispos       Date:  2000-12       Impact factor: 3.922

Review 4.  Calcium channel antagonists: clinical uses--past, present and future.

Authors:  David J Triggle
Journal:  Biochem Pharmacol       Date:  2007-01-13       Impact factor: 5.858

5.  A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro.

Authors:  J L Fayer; D M Petullo; B J Ring; S A Wrighton; K J Ruterbories
Journal:  J Pharmacol Toxicol Methods       Date:  2001 Sep-Oct       Impact factor: 1.950

6.  Dihydropyridine calcium-channel blockers for antihypertensive treatment in older patients--evidence from the Systolic Hypertension in Europe Trial.

Authors:  J A Staessen; L Thijs; H Celis; J Gasowski; J G Wang; R H Fagard
Journal:  S Afr Med J       Date:  2001-12

7.  Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates.

Authors:  S Ekins; G Bravi; J H Wikel; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1999-10       Impact factor: 4.030

8.  Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines.

Authors:  F P Guengerich; R H Böcker
Journal:  J Biol Chem       Date:  1988-06-15       Impact factor: 5.157

9.  In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam.

Authors:  Jun Tang; K Amin Usmani; Ernest Hodgson; Randy L Rose
Journal:  Chem Biol Interact       Date:  2004-04-15       Impact factor: 5.192

10.  Quantitative structure-activity relationship study of recently synthesized 1,4-dihydropyridine calcium channel antagonists. Application of the Hansch analysis method.

Authors:  Bahram Hemmateenejad; Ramin Miri; Morteza Akhond; Mojtaba Shamsipur
Journal:  Arch Pharm (Weinheim)       Date:  2002-12       Impact factor: 3.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.